Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30078
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNguyen, Mike-
dc.contributor.authorSegelov, Eva-
dc.contributor.authorGoldstein, David-
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorShapiro, Jeremy-
dc.contributor.authorPrice, Timothy J-
dc.contributor.authorNagrial, Adnan-
dc.contributor.authorChantrill, Lorraine-
dc.contributor.authorLeong, Trevor-
dc.contributor.authorChen, John-
dc.contributor.authorBurge, Matt-
dc.contributor.authorKarapetis, Christos S-
dc.contributor.authorChau, Ian-
dc.contributor.authorLordick, Florian-
dc.contributor.authorRenouf, Daniel-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorRoy, Amitesh C-
dc.date2021-
dc.date.accessioned2022-06-22T06:51:35Z-
dc.date.available2022-06-22T06:51:35Z-
dc.date.issued2022-01-
dc.identifier.citationExpert Review of Anticancer Therapy 2022; 22(1): 39-51en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30078-
dc.description.abstractPancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localized and advanced pancreatic cancer and offers an expert opinion on current best practice. For patients with localized disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resectable, borderline resectable, and locally advanced disease. Advances in metastatic disease are discussed including cytotoxic chemotherapy, targeted therapies, and the role of genomic testing to identify patients with molecular alterations. Reviewed literature included journal publications, abstracts presented at major international oncology meetings, and ongoing clinical trials databases. Pancreatic cancer is a devastating diagnosis and despite recent advances has a very poor prognosis. Only a minority of patients, 20%, are diagnosed with potentially curable disease. The shifting paradigm toward neoadjuvant therapy may improve resectability and survival rates; however, robust evidence is required. Thus far, there has only been limited progress in advanced stage disease. Genomic testing may potentially identify more treatment targets although limited to small subgroups.en
dc.language.isoeng
dc.subjectPancreatic canceren
dc.subjectadjuvanten
dc.subjectneoadjuvanten
dc.subjectreviewen
dc.subjectsurvivalen
dc.titleUpdate on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert Review of Anticancer Therapyen
dc.identifier.affiliationDepartment of Haematology and Oncology, The Queen Elizabeth Hospital/University of Adelaide, Adelaide, Australia..en
dc.identifier.affiliationDepartment of Medical Oncology, Prince of Wales Hospital, University of NSW, Sydney, Australia..en
dc.identifier.affiliationFlinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Australia..en
dc.identifier.affiliationDepartment of Cancer Care Services, Royal Brisbane Hospital, University of Queensland, Herston, Australia..en
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.affiliationDepartment Medical Oncology, Wollongong Hospital, Illawarra Shoalhaven Local Health District, Australia..en
dc.identifier.affiliationDivision of Radiation Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia..en
dc.identifier.affiliationDepartment of Medicine, Royal Marsden Hospital, Institute of Cancer Research, Surrey, London, UK..en
dc.identifier.affiliationDepartment of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney, Australia..en
dc.identifier.affiliationCabrini Health, Monash University, Melbourne, Australia..en
dc.identifier.affiliationDepartment of Medical Oncology, Westmead & Blacktown Hospitals, University of Sydney, Sydney, Australia..en
dc.identifier.affiliationDepartment of Medical Oncology, School of Clinical Sciences, Monash University and Monash Health, Melbourne, Australia..en
dc.identifier.affiliationUniversity Cancer Center Leipzig and Department of Oncology, Gastroenterology, Hepatology, Pneumology and Infectious Diseases, Leipzig University Medical Center, Leipzig, Germany..en
dc.identifier.affiliationDepartment of Medical Oncology, BC Cancer. Faculty of Medicine, University of British Columbia, Vancouver, Canada..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34739362/en
dc.identifier.doi10.1080/14737140.2022.2002689en
dc.type.contentTexten
dc.identifier.orcid0000-0003-3044-1707en
dc.identifier.orcid0000-0002-3922-2693en
dc.identifier.orcid0000-0003-2613-5168en
dc.identifier.pubmedid34739362
local.name.researcherNguyen, Mike
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on May 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.